WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
JERSEY CITY, N.J., Jan. 31, 2024 /PRNewswire/ — WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc., (“60P,”NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, has completed its previously announced Public Offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre‑funded units (the “Pre‑Funded Units”) at a price to the public of $0.375 per Pre‑Funded Unit.
Related news for (SXTP)
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 24/7 Market News Snapshot 15 July, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)
- 60 Degrees Pharmaceuticals Targets Human and Canine Babesiosis Markets With Tafenoquine
- Today’s Top Performers: MoBot’s Market Review 07/15/25 07:00 AM
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion